COVID-19 pneumonia. COVID-19, virus identified
Conditions
Interventions
Intervention 1: Intervention group: therapeutic regime including hydroxychloroquine 400 mg stat and lopinavir/ritonavir and250 mcg interferon beta 1 b subcutaneous injection every other day for at lea
Sponsors
Mazandaran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Inclusion criteria are adults over the age of 18 with a diagnosis of COVID-19 based on clinical criteria (presence of any symptoms of cough, shortness of breath, fever, and CT scan of the lung for evidence of involvement consistent with COVID-19 infection) or PCR.
Exclusion criteria
Exclusion criteria: History of allergy to any drugs of therapeutic regimen pregnancy and lactation renal and hepatic disease History of cerebral or ocular bleeding Glomerular infiltration less than 30 ml / min History of use of pentoxifylline Symptoms start more than 14 days before
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical response to therapeutic regimen by respiratory rate. Timepoint: Before intervention and daily during the study. Method of measurement: physical exam.;Clinical response to therapeutic regimen by blood oxygen saturation. Timepoint: Before intervention and daily during the study. Method of measurement: pulse oximeter.;Clinical response to therapeutic regimen by fever recovery. Timepoint: Before intervention and daily during the study. Method of measurement: thermometer.;Therapeutic regimen safety. Timepoint: Daily during the study. Method of measurement: patient tolerability.;Clinical response to therapeutic regimen by LDH level reduction. Timepoint: before intervention and then three times weekly during the study. Method of measurement: LDH laboratory kite.;Clinical response to therapeutic regimen by CRP level reduction. Timepoint: before intervention and then three times weekly during the study. Method of measurement: CRP laboratory kite.;Clinical response to therapeutic regimen by lymphocyte count recovery. Timepoint: before intervention and then daily during the study. Method of measurement: Cell blood count test. | — |
Secondary
| Measure | Time frame |
|---|---|
| Hospital stay duration. Timepoint: End of treatment. Method of measurement: Patient file.;Mortality rate. Timepoint: Daily during the study. Method of measurement: patient file.;IL-6 concentration. Timepoint: The first and fifth day of hospitalization. Method of measurement: ELISA kit.;Total antioxidant level. Timepoint: The first and fifth day of hospitalization. Method of measurement: Spectroscopy.;Carbonyl protein. Timepoint: The first and fifth day of hospitalization. Method of measurement: Spectroscopy.;Lipid peroxidation rate. Timepoint: The first and fifth day of hospitalization. Method of measurement: Spectroscopy.;Glutathione concentration. Timepoint: The first and fifth day of hospitalization. Method of measurement: Spectroscopy. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public Contact????? ???????
Mazandaran University of Medical Sciences
Outcome results
None listed